medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2025, Number 4

<< Back Next >>

Ginecol Obstet Mex 2025; 93 (4)

The transdermal contraceptive patch; Narrative review of the current state of its uses

Rosales OS, Velázquez RN, Campos GZ, Chapa KAM, Córdova GRA, Corona LR, Guerrero CFJ, Huerta CFR, Santoyo HS

Language: Spanish
References: 75
Page: 123-134
PDF size: 312.09 Kb.


ABSTRACT

Objective: To describe the current state of use of the transdermal contraceptive patch.
Methodology: Bibliographic review performed in two databases: PubMed and Google Scholar of articles published from 2001 to 2023, in English and Spanish, using MeSH terms: "transdermal contraception, contraceptive patch, norgestromin and ethinyl estradiol". The articles were selected and analyzed by nine obstetrician-gynecologists for a narrative review using six questions.
Results: 84 articles were found on contraception with norgestromin and ethinyl estradiol in the form of a transdermal patch. 17 were eliminated. Of the 67 articles selected; (: 17 were review articles, 49 were clinical trials, and one was a clinical practice guideline.
Conclusions: The transdermal contraceptive patch is a pharmacological intervention with contraceptive efficacy and multiple therapeutic actions, similar to those of other combined hormonal contraceptives.


REFERENCES

  1. Comisión Económica para América Latina y el Caribe(CEPAL), Observatorio Demográfico, 2022 (LC/PUB.2022/13-P), Santiago, 2022. https:www.cepal.org/es/publicaciones/48488-observatorio-demografico-americalatina.caribe-2022-tendencias-la poblacion#~:text=La%20edicion%20del%20Observatorio%20Demografico%20correspondiente%20a%202022,y%20territotios%20de%20América%20Latina%20y%20el%20Caribe.

  2. Planificación Familiar/ métodos anticonceptivos OMS Datosy Cifras. 5 de septiembre de 2023. https://www.who.int/es/news-room/fact-sheets/detail/family-planningcontraception.

  3. ENADID Resultados 2014. https://Encuesta Nacional de laDinámica Demográfica. ENADID 2014. Principales resultados(inegi.org.mx).

  4. ENADID Resultados 2018. https://.

  5. Food and Drug Administration. Approval Letter: Ortho-Evra (NDA #021-180). November 21, 2001. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/021-180_ORTHO.cfm.

  6. Comparativo venta total anual global EVRA. Datos auditadosGedeon Richter plc. Octubre 2023.

  7. Situación de la Salud Sexual y Reproductiva. RepúblicaMexicana CONAPO 2016. https://.

  8. Meneses E, Ailines F, Hernández MF. Factores que influyenen el conocimiento funcional de métodos anticonceptivos,2014. En: La situación demográfica de México2017. Consejo Nacional de Población, julio de 2018, pp65-92 https://www.gob.mx/cms/uploads/attachment/file/398675/04_Meneses_Alines_Hernandez.pdf.

  9. Abrams D. Skee, K Talluri, et al. Bioavailability of17-deacetylnorgestimate (17D-NGM) and ethinyl estradiol(EE) from a contraceptive patch FASEB J 2000; 14: A1479.https://doi.org/ 10.1046/j.0306-5251.2001.01532.x.

  10. Dittrich R, Parker L, Rosen JB, et al. Ortho Evra/Evra 001Study Group. Transdermal contraception: evaluationof three transdermal norelgestromin/ethinyl estradioldoses in a randomized, multicenter, dose-response study.Am J Obstet Gynecol 2002; 186 (1): 15-20. https://doi.org/10.1067/mob.2002.118844.

  11. Galzote RM, Rafie S, Teal R, et al. Transdermal delivery ofcombined hormonal contraception: a review of the currentliterature. Int J Womens Health 2017; 9:315-321. https://doi.org/10.2147/IJWH.S102306.

  12. Burkman RT. The transdermal contraceptive system. Am JObstet Gynecol 2004; 190 (4 Suppl): S49-53. https://doi.org/10.1016/j.ajog.2004.01.060.

  13. Burkman RT. Transdermal hormonal contraception: benefitsand risks. Am J Obstet Gynecol 2007; 197 (2): 134.e1-6.https://doi.org/10.1016/j.ajog.2007.04.027.

  14. Goa KL, Warner GT, Easthope SE. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonalcontraception. Treat Endocrinol 2003; 2 (3): 191-206.https://doi.org/10.2165/00024677-200302030-00005.

  15. Pierson RA, Archer DF, Moreau M, et al. Ortho Evra/Evraversus oral contraceptives: follicular development and ovulationin normal cycles and after an intentional dosing error.Fertil Steril 2003; 80 (1): 34-42. https://doi.org/10.1016/s0015-0282 (03)00556-9.

  16. Dittrich R, Parker L, Rosen JB, et al. Ortho Evra/Evra 001Study Group. Transdermal contraception: evaluation ofthree transdermal norelgestromin/ethinyl estradiol dosesin a randomized, multicenter, dose-response study. AmJ Obstet Gynecol 2002 Jan; 186 (1): 15-20. https://doi.org/10.1067/mob.2002.118844.

  17. Abrams LS, Skee D, Natarajan J, et al. Pharmacokinetic overviewof Ortho Evra/Evra. Fertil Steril 2002; 77 (2 Suppl 2):S3-12. https://doi.org/10.1016/s0015-0282 (01)03261-7.

  18. Faculty of Family Planning and Reproductive HealthCare Clinical Effectiveness Unit. New Product Review(September 2003). Norelgestromin/ethinyl oestradioltransdermal contraceptive system (Evra). J FamPlann Reprod Health Care 2004; 30 (1): 43-5. https://doi.org/10.1783/147118904322701974.

  19. Hernandez-Juarez J, Garcia-Latorre EA, Moreno-HernandezM, et al. Metabolic effects of the contraceptive skin patchand subdermal contraceptive implant in Mexican women:a prospective study. Reprod Health 2014; 11:33. do https://doi.org/10.1186/1742-4755-11-33.

  20. Graziottin A. A review of transdermal hormonal contraception:focus on the ethinylestradiol/norelgestromincontraceptive patch. Treat Endocrinol 2006; 5 (6): 359-65.https://doi.org/10.2165/00024677-200605060-00004.

  21. Smallwood GH, Meador ML, Lenihan JP, et al. ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermalcontraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1):799-805. https://doi.org/10.1016/s0029-7844 (01)01534-4.

  22. Creasy GW, Abrams LS, Fisher AC. Transdermal contraception.Semin Reprod Med 2001; 19 (4): 373-80. https://doi.org/10.1055/s-2001-18645.

  23. Nelson AL. Transdermal contraception methods: today'spatches and new options on the horizon. Expert OpinPharmacother 2015; 16 (6): 863-73. https://doi.org/10.1517/14656566.2015.1022531.

  24. Jakimiuk AJ, Crosignani PG, Chernev T, et al. High levels ofwomen's satisfaction and compliance with transdermalcontraception: results from a European multinational,6-month study. Gynecol Endocrinol 2011; 27 (10): 849-56.https://doi.org/10.3109/09513590.2010.538095.

  25. Stewart FH, Kaunitz AM, Laguardia KD, et al. Extendeduse of transdermal norelgestromin/ethinyl estradiol: arandomized trial. Obstet Gynecol 2005; 105 (6): 1389-96.https://doi.org/10.1097/01.AOG.0000160430.61799.f6

  26. Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernández-RuizMA, et al. Anticoncepción con hormonales combinadosen ciclos extendidos artificialmente [Combined hormonalcontraception in cycles artificially extended]. Ginecol ObstetMex 2010; 78 (1): 37-45. PMID: 20931801.

  27. Lavelanet AF, Rybin D, White KO. The pharmacokinetics of12-week continuous contraceptive patch use. Contraception.2017; 95 (6): 578-585. https://doi.org/10.1016/j.contraception.2017.03.002.

  28. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptiveefficacy and cycle control with the Ortho Evra/Evratransdermal system: the analysis of pooled data. FertilSteril 2002; 77 (2 Suppl 2): S13-8. https://doi.org/10.1016/s0015-0282 (01)03275-7.

  29. Faculty of Family Planning and Reproductive Health CareClinical Effectiveness Unit. New Product Review (September2003). Norelgestromin/ethinyl oestradiol transdermalcontraceptive system (Evra). J Fam Plann Reprod HealthCare 2004; 30 (1): 43-5. https://doi.org/10.1783/147118904322701974.

  30. Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginalring versus combined oral contraceptives for contraception.Cochrane Database Syst Rev 2013; 2013 (4): CD003552.https://doi.org/10.1002/14651858.CD003552.pub4.

  31. Audet MC, Moreau M, Koltun WD, et al. ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacyand cycle control of a transdermal contraceptive patchvs an oral contraceptive: a randomized controlled trial.JAMA 2001; 285 (18): 2347-54 https://doi.org/10.1001/jama.285.18.2347.

  32. Crosignani PG, Nappi C, Ronsini S, et al. Italian EVRA ContrastStudy Group. Satisfaction and compliance in hormonalcontraception: the result of a multicentre clinical study onwomen's experience with the ethinylestradiol/norelgestromincontraceptive patch in Italy. BMC Womens Health.2009; 30; 9:18. https://doi.org/10.1186/1472-6874-9-18.

  33. Weisberg F, Bouchard C, Moreau M, et al. NRGEEP-CON-401Study Group. Preference for and satisfaction of Canadianwomen with the transdermal contraceptive patch versusprevious contraceptive method: an open-label, multicentrestudy. J Obstet Gynaecol Can 2005; 27 (4): 350-9. https://doi.org/10.1016/s1701-2163 (16)30462-5

  34. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact ofimproved compliance with a weekly contraceptive transdermalsystem (Ortho Evra) on contraceptive efficacy. Contraception2004; 69 (3): 189-95. https://doi.org/10.1016/j.contraception.2003.10.006

  35. Archer DF, Bigrigg A, Smallwood GH, et al. Assessmentof compliance with a weekly contraceptive patch (OrthoEvra/Evra) among North American women. Fertil Steril2002 Feb; 77 (2 Suppl 2): S27-31. https://doi.org/10.1016/s0015-0282 (01)03263-0.

  36. Abrams LS, Skee DM, Natarajan J, et al. Multiple-dose pharmacokineticsof a contraceptive patch in healthy womenparticipants. Contraception 2001; 64 (5): 287-294. https://doi.org/10.1016/s0010-7824 (01)00273-6.

  37. Zacur HA, Hedon B, Mansour D, et al. Integrated summaryof Ortho Evra/Evra contraceptive patch adhesion in variedclimates and conditions. Fertil Steril 2002; 77 (2 Suppl 2):S32-5. https://doi.org/10.1016/s0015-0282 (01)03262-9.

  38. Piyasirisilp R, Taneepanichskul S. A clinical study of transdermalcontraceptive patch in Thai adolescence women.J Med Assoc Thai 2008; 91 (2): 137-41. PMID: 18389975.

  39. Abrams LS, Skee DM, Wong FA, et al. Pharmacokinetics ofnorelgestromin and ethinyl estradiol from two consecutivecontraceptive patches. J Clin Pharmacol 2001; 41 (11):1232-7. https://doi.org/10.1177/00912700122012788.

  40. Abrams LS, Skee DM, Natarajan J, et al. Pharmacokineticsof norelgestromin and ethinyl estradiol delivered by acontraceptive patch (Ortho Evra/Evra) under conditions ofheat, humidity, and exercise. J Clin Pharmacol 2001; 41 (12):1301-9. https://doi.org/10.1177/00912700122012887.

  41. Graziottin A. Safety, efficacy and patient acceptability ofthe combined estrogen and progestin transdermal contraceptivepatch: a review. Patient Prefer Adherence 2008;2:357-67. https://doi.org/10.2147/ppa.s3233.

  42. O'Connell K, Burkman RT. The transdermal contraceptivepatch: an updated review of the literature. Clin ObstetGynecol 2007; 50 (4): 918-26. https://doi.org/10.1097/GRF.0b013e318159c410.

  43. Gruber D, Skřivánek A, Serrani M, et al. A comparison ofbleeding patterns and cycle control using two transdermalcontraceptive systems: a multicenter, open-label, randomizedstudy. Contraception 2015; 91 (2): 105-12. https://doi.org/10.1016/j.contraception.2014.10.003.

  44. Sibai BM, Odlind V, Meador ML, et al. A comparative andpooled análisis of the safety and tolerability of the contraceptivepatch (Ortho Evra/Evra). Fertil Steril 2002; 77(2 suppl 2): S19-26. https://doi.org/10.1016/s0015-0282(01)03264-2.

  45. Suwanmalee O, Taneepanichskul S. A clinical study of transdermalcontraceptive patch in Thai women. J Med AssocThai 2006; 89 Suppl 4:S1-4. PMID: 17726805.

  46. Sanga M, Vaughan S, Nangosyah J, et al. Randomized,double-blind, two-way crossover bioequivalence and adhesionstudy, in healthy women, of a transdermal contraceptivepatch with a newly sourced adhesive component atthe end of shelf life vs. the EVRA patch at the beginningof shelf life. Int J Clin Pharmacol Ther 2022; 60 (1): 67-78.https://doi.org/10.5414/CP204034

  47. Parasrampuria DA, Vaughan S, Ariyawansa J, et al. Comparisonof a transdermal contraceptive patch with a newlysourced adhesive component versus EVRA patch: A doubleblind,randomized, bioequivalence and adhesion study inhealthy women. Contraception 2020; 101 (4): 276-282.https://doi.org/10.1016/j.contraception.2019.12.012

  48. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venousthromboembolism in women using a contraceptivetransdermal patch and oral contraceptives containingnorgestimate and 35 microg of ethinyl estradiol. Contraception2006; 73 (3): 223-8. https://doi.org/10.1016/j.contraception.2006.01.001.

  49. Jick S, Kaye JA, Li L, e al. Further results on the risk ofnonfatal venous thromboembolism in users of the contraceptivetransdermal patch compared to users of oralcontraceptives containing norgestimate and 35 microg ofethinyl estradiol. Contraception 2007; 76 (1): 4-7 https://doi.org/10.1016/j.contraception.2007.03.003.

  50. Keenan L, Kerr T, Duane M, et al. Systematic Review ofHormonal Contraception and Risk of Venous Thrombosis.Linacre Q 2018; 85 (4): 470-477. https://doi.org/10.1177/0024363918816683.

  51. Sidney S, Cheetham TC, Connell FA, et al. Recent combinedhormonal contraceptives (CHCs) and the risk ofthromboembolism and other cardiovascular events innew users. Contraception 2013; 87 (1): 93-100. https://doi.org/10.1016/j.contraception.2012.09.015.

  52. Heikinheimo O, Toffol E, Partonen T, et al. Systemic hormonalcontraception and risk of venous thromboembolism.Acta Obstet Gynecol Scand 2022; 101 (8): 846-855. https://doi.org/10.1111/aogs.14384.

  53. Creasy GW, Fisher AC, Hall N, et al. Transdermal contraceptivepatch delivering norelgestromin and ethinyl estradiol.Effects on the lipid profile. J Reprod Med 2003; 48 (3):179-86. PMID: 12698776.

  54. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptiveefficacy and cycle control with the Ortho Evra/Evratransdermal system: the analysis of pooled data. FertilSteril 2002; 77 (2 Suppl 2): S13-8. https://doi.org/10.1016/s0015-0282 (01)03275-7.

  55. Burkman RT. The transdermal contraceptive patch: a newapproach to hormonal contraception. Int J Fertil WomensMed 2002; 47 (2): 69-76. PMID: 11991433.

  56. Abrams LS, Skee DM, Natarajan J, et al. Pharmacokineticsof a contraceptive patch (Evra/Ortho Evra) containingnorelgestromin and ethinyloestradiol at four applicationsites. Br J Clin Pharmacol 2002; 53 (2): 141-6. https://doi.org/10.1046/j.0306-5251.2001.01532.x.

  57. Fleischer K, van Vliet HA, Rosendaal FR, et al. Effects ofthe contraceptive patch, the vaginal ring and an oralcontraceptive on APC resistance and SHBG: a cross-overstudy. Thromb Res 2009; 123 (3): 429-35. https://doi.org/10.1016/j.thromres.2008.04.022.

  58. Maguire K, Westhoff C. The state of hormonal contraceptiontoday: established and emerging noncontraceptivehealth benefits. Am J Obstet Gynecol 2011; 205 (4 Suppl):S4‐S8. https://doi.org/10.1016/j.ajog.2011.06.056.

  59. Kiley J, Hammond C. Combined oral contraceptives:a comprehensive review. Clin Obstet Gynecol2007; 50 (4): 868-77. https://doi.org/10.1097/GRF.0b013e318159c06a.

  60. FSRH Guideline (January 2019) Combined Hormonal Contraception(Revision due by January 2024). BMJ Sex ReprodHealth 2019; 45 (Suppl 1): 1-93. https://doi.org/10.1136/bmjsrh-2018-CHC.

  61. Murillo-Zamora E, Mendoza-Cano O, Guzmán-Esquivel J,et al. Trends in Teen Births in Mexico Spanning 25 Years: ANeed for Regionally-directed Preventive Strategies. ArchMed Res 2019; 50 (3): 142-150. https://doi.org/10.1016/j.arcmed.2019.07.008.

  62. Chabbert-Buffet N, Marret H, Agostini A, et al. Clinical practiceguidelines for contraception by the French NationalCollege of Gynecologists and Obstetricians (CNGOF). JGynecol Obstet Hum Reprod 2019; 48 (7): 441-454. https://doi.org/10.1016/j.jogoh.2019.04.009.

  63. Dokras A. Noncontraceptive use of oral combined hormonalcontraceptives in polycystic ovary syndrome-risksversus benefits. Fertil Steril 2016; 106 (7): 1572-1579.https://doi.org/10.1016/j.fertnstert.2016.10.027.

  64. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermalsteroidal contraceptives on androgenic markers.Am J Obstet Gynecol 2005; 192 (6): 2055-9. https://doi.org/10.1016/j.ajog.2005.02.067.

  65. Requena C, Llombart B. Oral Contraceptives in Dermatology.Actas Dermosifiliogr (Engl Ed) 2020; 111 (5): 351-356.https://doi.org/10.1016/j.ad.2019.06.006.

  66. Harper JC. Use of Oral Contraceptives for Managementof Acne Vulgaris: Practical Considerations in Real WorldPractice. Dermatol Clin 2016; 34 (2): 159-65. https://doi.org/10.1016/j.det.2015.11.005.

  67. Arowojolu AO, Gallo MF, Grimes DA, et al. Combinedoral contraceptive pills for treatment of acne. CochraneDatabase Syst Rev. 2004; (3): CD004425. https://doi.org/10.1002/14651858.CD004425.pub2.

  68. Vercellini P, Barbara G, Somigliana E, et al. Comparison ofcontraceptive ring and patch for the treatment of symptomaticendometriosis. Fertil Steril 2010; 93 (7): 2150-61.https://doi.org/10.1016/j.fertnstert.2009.01.071.

  69. Lopez LM, Grimes DA, Schulz KF, et al. Steroidal contraceptives:effect on bone fractures in women. CochraneDatabase Syst Rev 2006; 4:CD006033. https://doi.org/10.1002/14651858.CD006033.pub2.

  70. Massaro M, Di Carlo C, Gargano V, et al. Effects of thecontraceptive patch and the vaginal ring on bone metabolismand bone mineral density: a prospective, controlled,randomized study. Contraception 2010; 81 (3): 209-14.https://doi.org/10.1016/j.contraception.2009.09.011.

  71. Xia YY, Gronwald J, Karlan B, et al. Hereditary OvarianCancer Clinical Study Group. Contraceptive use and the riskof ovarian cancer among women with a BRCA1 or BRCA2mutation. Gynecol Oncol 2022; 164 (3): 514-521. https://doi.org/10.1016/j.ygyno.2022.01.014.

  72. Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestinand estrogen potency of combination oralcontraceptives and endometrial cancer risk. GynecolOncol 2006; 103 (2): 535-40. https://doi.org/10.1016/j.ygyno.2006.03.046.

  73. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptiveefficacy of oral and transdermal hormones when coadministeredwith protease inhibitors in HIV-1-infectedwomen: pharmacokinetic results of ACTG trial A5188. JAcquir Immune Defic Syndr 2010; 55 (4): 473-82. https://doi.org/10.1097/QAI.0b013e3181eb5ff5.

  74. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z, et al. Oraland transdermal hormonal contraception in women afterkidney transplantation. Transplant Proc 2007; 39 (9): 2759-62. https://doi.org/10.1016/j.transproceed.2007.09.014.

  75. White T, Ozel B, Jain JK, et al. Effects of transdermal and oralcontraceptives on estrogen-sensitive hepatic proteins. Contraception2006; 74 (4): 293-6. https://doi.org/10.1016/j.contraception.2006.04.005.




2020     |     www.medigraphic.com